Cereno Scientific, a company that develops treatments for common and rare cardiovascular disease, entered into an agreement with CordenPharma, a contract development and manufacturing organization (CDMO), to manufacture drug candidate CS1 in larger quantities that are needed to ensure supply to conduct the next clinical trial and later when approved for market launch. A request for extended access (compassionate use) for the use of CS1 is currently under consideration by the FDA, which, if ac...